SeekingAlpha · Aug 11, 2026
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading
AbCellera pivots to its own pipeline with ABCL635 for menopausal hot flashes. Read the latest analysis on the stock here.
AB
NASDAQ · ABCL
AbCellera Biologics Inc.
Healthcare · Biotechnology
$11.38
Up+$0.41 (+3.74%)
Updated Aug 16, 2026, 3:26 AM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.08B
- P/E ratio
- -7.37
- Dividend yield
- 0.00%
- 52-week range
- $3.22 – $11.50
- Volume
- 12.38M
- Avg. volume
- 4.11M
Price performance
ABCL price history
1M range · 20 trading sessions · Daily adjusted prices
ABCL closed at $11.38 after 20 trading sessions, up 96.21% for the selected period.
- Last close
- $11.38
- Period change
- +96.21%
- Period low
- $5.25
- Period high
- $11.38
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 14, 2026 | $10.84 | $11.50 | $10.47 | $11.38 | 12.38M |
| Aug 13, 2026 | $10.32 | $11.065 | $10.22 | $10.97 | 20.13M |
| Aug 12, 2026 | $9.22 | $10.38 | $9.00 | $10.355 | 14.85M |
| Aug 11, 2026 | $9.42 | $10.29 | $9.02 | $9.76 | 18.37M |
| Aug 10, 2026 | $8.76 | $10.01 | $8.40 | $9.34 | 46.04M |
| Aug 7, 2026 | $6.65 | $6.99 | $6.35 | $6.93 | 6.82M |
| Aug 6, 2026 | $5.79 | $6.565 | $5.62 | $6.53 | 8.41M |
| Aug 5, 2026 | $6.05 | $6.21 | $5.84 | $5.92 | 4.63M |
| Aug 4, 2026 | $5.97 | $6.14 | $5.87 | $6.09 | 3.97M |
| Aug 3, 2026 | $5.705 | $6.045 | $5.565 | $5.83 | 3.41M |
| Jul 31, 2026 | $5.70 | $5.87 | $5.51 | $5.71 | 5.01M |
| Jul 30, 2026 | $5.53 | $5.72 | $5.35 | $5.69 | 4.34M |
| Jul 29, 2026 | $5.34 | $5.58 | $5.225 | $5.39 | 6.06M |
| Jul 28, 2026 | $5.20 | $5.385 | $4.98 | $5.29 | 6.08M |
| Jul 27, 2026 | $5.405 | $5.50 | $5.24 | $5.25 | 4.23M |
| Jul 24, 2026 | $5.67 | $5.74 | $5.29 | $5.31 | 6.27M |
| Jul 23, 2026 | $5.69 | $5.87 | $5.60 | $5.67 | 2.89M |
| Jul 22, 2026 | $5.92 | $6.06 | $5.71 | $5.73 | 2.56M |
| Jul 21, 2026 | $5.815 | $6.05 | $5.54 | $5.97 | 5.13M |
| Jul 20, 2026 | $6.34 | $6.47 | $5.785 | $5.80 | 6.37M |
Latest ABCL news
The latest Smart Investors Daily articles mentioning ABCL.
Stock researchCompany · Overview
ABCL research
Overview
Company profile and research snapshot.
Company profile
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $20.17
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | Truist Securities | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Aug 6, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 7, 2026 | Benchmark | Buy | — |
| May 5, 2026 | Cantor Fitzgerald | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 11, 2026
AbCellera Biologics Commences Underwritten Public Offering Of $200M Of Its Common Shares
AbCellera Biologics Inc. (NASDAQ:ABCL) ("AbCellera") today announced that it has commenced an underwritten public offering of $200.0 million of its common shares and, in lieu of common shares to certain
Benzinga · Aug 11, 2026
Truist Securities Maintains Buy on AbCellera Biologics, Raises Price Target to $30
Truist Securities analyst Robyn Kamaus maintains AbCellera Biologics (NASDAQ:ABCL) with a Buy and raises the price target from $12 to $30.
SeekingAlpha · Aug 10, 2026
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript
AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes August 10, 2026 7:30 AM...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
